Key Takeaways
- • Graph Therapeutics has secured $5 million in Series funding led by Daphni, bringing total capitalization to over $10 million including non-dilutive grants from Austrian public agencies (FFG and AWS).
- • The company operates a proprietary "lab-in-the-loop" AI platform that combines perturbation modeling, multi-omics profiling, and machine learning to identify disease mechanisms and therapeutic targets from live patient tissue samples.
- • Graph's investor syndicate includes Daphni, SquareOne, Merantix Capital, and NAVEC Investment Management, indicating strong backing from both European venture and specialized biotech-focused funds.
- • The platform has achieved substantial validation and de-risking through clinically relevant biological models, positioning the company for internal pipeline advancement and strategic partnership opportunities.
- • Graph targets precision medicine applications in inflammatory and immune-mediated diseases, a sector with significant unmet clinical and commercial demand.
Summary
Graph Therapeutics, a techbio company focused on precision immunology, has completed a $5 million investment round led by Paris-based venture capital firm Daphni, elevating the company's total funding to more than $10 million. The round included capital from existing investors SquareOne, Merantix Capital, and NAVEC Investment Management, and was supplemented by non-dilutive grant funding from the Austrian Research Promotion Agency (FFG) and Austria Wirtschaftsservice (AWS), demonstrating both private confidence in the venture and public sector support for its research infrastructure.
The company's core technology centers on a proprietary "lab-in-the-loop" AI platform designed to decode immune dysfunction by analyzing complex live patient samples. Graph's methodology integrates perturbation modeling, functional and multi-omics profiling, and advanced machine learning to generate mechanistic insights directly from patient tissue. This approach enables the identification of disease mechanisms, novel therapeutic targets, and biomarkers that inform the development of differentiated therapies, positioning the company within the broader precision medicine and AI-driven drug discovery landscape.
According to the company's assessment, Graph has substantially de-risked and validated its platform through clinically relevant biological models, creating a foundation for advancing an internal pipeline of therapeutics targeting complex inflammatory and immune-mediated diseases. The maturity of the platform also creates pathways for strategic partnerships and out-licensing agreements, potentially extending the company's commercial reach beyond its proprietary development efforts. This capital structure and operational positioning suggest Graph is transitioning from early validation phases toward clinical and commercial execution, with institutional backing reflective of confidence in both the technology and the market opportunity in precision immunology.
The company's core technology centers on a proprietary "lab-in-the-loop" AI platform designed to decode immune dysfunction by analyzing complex live patient samples. Graph's methodology integrates perturbation modeling, functional and multi-omics profiling, and advanced machine learning to generate mechanistic insights directly from patient tissue. This approach enables the identification of disease mechanisms, novel therapeutic targets, and biomarkers that inform the development of differentiated therapies, positioning the company within the broader precision medicine and AI-driven drug discovery landscape.
According to the company's assessment, Graph has substantially de-risked and validated its platform through clinically relevant biological models, creating a foundation for advancing an internal pipeline of therapeutics targeting complex inflammatory and immune-mediated diseases. The maturity of the platform also creates pathways for strategic partnerships and out-licensing agreements, potentially extending the company's commercial reach beyond its proprietary development efforts. This capital structure and operational positioning suggest Graph is transitioning from early validation phases toward clinical and commercial execution, with institutional backing reflective of confidence in both the technology and the market opportunity in precision immunology.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.